Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00440

Submission Number:
00440
Commenter:
George Warren
State:
Florida
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
I oppose this merger. Allowing CVS Pharmacies access to Aetna PHI is wrong. The CVS - Caremark merger was a mistake. I have seen my pharmacys patients contacted by CVS after I fill their prescriptions to switch or transfer these same prescriptions to one of their pharmacies. The questions that should be asked is, How did CVS know what prescriptions were filled at an independent pharmacy? Is this Caremark PHI being shared between companies? Allowing CVS and Aetna to merge will create unfair competition and eventually eliminate their competition (me) and drive prices higher as the PBM (CVS/Caremark) greedier. Quality outcomes are impossible at this level. One to one encounters, where we talk to our patients and become problem solvers, is where health care should be.